Aurora B kinase is a potent and selective target in MYCN-driven neuroblastoma

Despite advances in multimodal treatment, neuroblastoma (NB) is often fatal for children with high-risk disease and many survivors need to cope with long-term side effects from high-dose chemotherapy and radiation. To identify new therapeutic targets, we performed an siRNA screen of the druggable genome combined with a small molecule screen of 465 compounds targeting 39 different mechanisms of actions in four NB cell lines. We identified 58 genes as targets, including AURKB, in at least one cell line. In the drug screen, aurora kinase inhibitors (nine molecules) and in particular the AURKB-selective compound, barasertib, were the most discriminatory with regard to sensitivity for MYCN-amplified cell lines. In an expanded panel of ten NB cell lines, those with MYCN-amplification and wild-type TP53 were the most sensitive to low nanomolar concentrations of barasertib. Inhibition of the AURKB kinase activity resulted in decreased phosphorylation of the known target, histone H3, and upregulation of TP53 in MYCN-amplified, TP53 wild-type cells. However, both wild-type and TP53 mutant MYCN-amplified cell lines arrested in G2/M phase upon AURKB inhibition. Additionally, barasertib induced endoreduplication and apoptosis. Treatment of MYCN-amplified/TP53 wild-type neuroblastoma xenografts resulted in profound growth inhibition and tumor regression. Therefore, aurora B kinase inhibition is highly effective in aggressive neuroblastoma and warrants further investigation in clinical trials.

[1]  J. Radford,et al.  A Phase 2 Trial of AZD1152 in Relapsed/Refractory Diffuse Large B-Cell Lymphoma , 2014 .

[2]  Ravi Radhakrishnan,et al.  ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastoma. , 2014, Cancer cell.

[3]  Erin F. Simonds,et al.  Drugging MYCN through an allosteric transition in Aurora kinase A. , 2014, Cancer cell.

[4]  R. Poon,et al.  p53 deficiency enhances mitotic arrest and slippage induced by pharmacological inhibition of Aurora kinases , 2014, Oncogene.

[5]  Sam Michael,et al.  High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell–like diffuse large B-cell lymphoma cells , 2014, Proceedings of the National Academy of Sciences.

[6]  S. Keir,et al.  Initial testing (stage 1) of the polo‐like kinase inhibitor volasertib (BI 6727), by the Pediatric Preclinical Testing Program , 2014, Pediatric blood & cancer.

[7]  H. Kantarjian,et al.  Stage I of a phase 2 study assessing the efficacy, safety, and tolerability of barasertib (AZD1152) versus low‐dose cytosine arabinoside in elderly patients with acute myeloid leukemia , 2013, Cancer.

[8]  S. Keir,et al.  Initial testing (stage 1) of the phosphatidylinositol 3′ kinase inhibitor, SAR245408 (XL147) by the pediatric preclinical testing program , 2013, Pediatric blood & cancer.

[9]  G. Shapiro,et al.  Phase I study of barasertib (AZD1152), a selective inhibitor of Aurora B kinase, in patients with advanced solid tumors , 2013, Investigational New Drugs.

[10]  W. Earnshaw,et al.  The chromosomal passenger complex (CPC): from easy rider to the godfather of mitosis , 2012, Nature Reviews Molecular Cell Biology.

[11]  Herbert Waldmann,et al.  A framework for identification of actionable cancer genome dependencies in small cell lung cancer , 2012, Proceedings of the National Academy of Sciences.

[12]  J. Maris,et al.  Pediatric Phase I Trial and Pharmacokinetic Study of MLN8237, an Investigational Oral Selective Small-Molecule Inhibitor of Aurora Kinase A: A Children's Oncology Group Phase I Consortium Study , 2012, Clinical Cancer Research.

[13]  Lesley A. Mathews,et al.  A 1536-Well Quantitative High-Throughput Screen to Identify Compounds Targeting Cancer Stem Cells , 2012, Journal of biomolecular screening.

[14]  M. Dennis,et al.  Phase I study of the Aurora B kinase inhibitor barasertib (AZD1152) to assess the pharmacokinetics, metabolism and excretion in patients with acute myeloid leukemia , 2012, Cancer Chemotherapy and Pharmacology.

[15]  Eugen C. Buehler,et al.  siRNA off-target effects in genome-wide screens identify signaling pathway members , 2012, Scientific Reports.

[16]  Ji-Hyun Shin,et al.  Aurora B kinase phosphorylates and instigates degradation of p53 , 2012, Proceedings of the National Academy of Sciences.

[17]  Eugen C. Buehler,et al.  Common Seed Analysis to Identify Off-Target Effects in siRNA Screens , 2012, Journal of biomolecular screening.

[18]  P. Sonneveld,et al.  Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia. , 2011, Blood.

[19]  T. Yamauchi,et al.  A Phase I study to assess the safety, pharmacokinetics and efficacy of barasertib (AZD1152), an Aurora B kinase inhibitor, in Japanese patients with advanced acute myeloid leukemia. , 2011, Leukemia research.

[20]  S. Robinson,et al.  The Aurora Kinase Inhibitor CCT137690 Downregulates MYCN and Sensitizes MYCN-Amplified Neuroblastoma In Vivo , 2011, Molecular Cancer Therapeutics.

[21]  Colin N. Dewey,et al.  RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome , 2011, BMC Bioinformatics.

[22]  R. Stallings,et al.  Dissection of the oncogenic MYCN transcriptional network reveals a large set of clinically relevant cell cycle genes as drivers of neuroblastoma tumorigenesis , 2011, Molecular carcinogenesis.

[23]  Aleksandar Milosavljevic,et al.  A genome-wide search for promoters that respond to increased MYCN reveals both new oncogenic and tumor suppressor microRNAs associated with aggressive neuroblastoma. , 2011, Cancer research.

[24]  Y. Okano,et al.  Effects of AZD1152, a selective Aurora B kinase inhibitor, on Burkitt's and Hodgkin's lymphomas. , 2011, Biochemical pharmacology.

[25]  A. Paradiso,et al.  Aurora B kinase inhibitor AZD1152: determinants of action and ability to enhance chemotherapeutics effectiveness in pancreatic and colon cancer , 2011, British Journal of Cancer.

[26]  Cynthia Winter,et al.  RNAi screen of the protein kinome identifies checkpoint kinase 1 (CHK1) as a therapeutic target in neuroblastoma , 2011, Proceedings of the National Academy of Sciences.

[27]  J. Schellens,et al.  Clinical evaluation of AZD1152, an i.v. inhibitor of Aurora B kinase, in patients with solid malignant tumors. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[28]  Ruili Huang,et al.  A Grid Algorithm for High Throughput Fitting of Dose-Response Curve Data , 2010, Current chemical genomics.

[29]  Ryan D. Morin,et al.  System-Level Analysis of Neuroblastoma Tumor–Initiating Cells Implicates AURKB as a Novel Drug Target for Neuroblastoma , 2010, Clinical Cancer Research.

[30]  Hong Liu,et al.  Therapeutic potential of a synthetic lethal interaction between the MYC proto-oncogene and inhibition of aurora-B kinase , 2010, Proceedings of the National Academy of Sciences.

[31]  Peter J Houghton,et al.  Initial testing of the aurora kinase a inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP) , 2010, Pediatric blood & cancer.

[32]  J. Maris.  Recent advances in neuroblastoma. , 2010, The New England journal of medicine.

[33]  S. Altekruse,et al.  Outcomes for children and adolescents with cancer: challenges for the twenty-first century. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  Mong-Hong Lee,et al.  Antineoplastic effects of an Aurora B kinase inhibitor in breast cancer , 2010, Molecular Cancer.

[35]  Nunzio Iraci,et al.  p53 is a direct transcriptional target of MYCN in neuroblastoma. , 2010, Cancer research.

[36]  M. Cole,et al.  High Frequency of p53/MDM2/p14ARF Pathway Abnormalities in Relapsed Neuroblastoma , 2010, Clinical Cancer Research.

[37]  S. Keir,et al.  Initial testing (stage 1) of the kinesin spindle protein inhibitor ispinesib by the pediatric preclinical testing program , 2009, Pediatric blood & cancer.

[38]  M. Furihata,et al.  Analysis of Aurora B kinase in non-Hodgkin lymphoma , 2009, Laboratory Investigation.

[39]  Meredith C Henderson,et al.  Synthetic lethal RNAi screening identifies sensitizing targets for gemcitabine therapy in pancreatic cancer , 2009, Journal of Translational Medicine.

[40]  J. Fitzgibbon,et al.  AZD1152 rapidly and negatively affects the growth and survival of human acute myeloid leukemia cells in vitro and in vivo. , 2009, Cancer research.

[41]  G. Schwartz,et al.  The Topoisomerase I Poison CPT-11 Enhances the Effect of the Aurora B Kinase Inhibitor AZD1152 both In vitro and In vivo , 2009, Clinical Cancer Research.

[42]  K. Matthay,et al.  Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  R. Beijersbergen,et al.  Stabilization of N-Myc is a critical function of Aurora A in human neuroblastoma. , 2009, Cancer cell.

[44]  Tony Reiman,et al.  The selective Aurora B kinase inhibitor AZD1152 is a potential new treatment for multiple myeloma , 2008, British journal of haematology.

[45]  Marc Ferrer,et al.  Median Absolute Deviation to Improve Hit Selection for Genome-Scale RNAi Screens , 2008, Journal of biomolecular screening.

[46]  S. Keir,et al.  Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program , 2008, Pediatric blood & cancer.

[47]  J. Bourhis,et al.  Enhancement of radiation response in p53-deficient cancer cells by the Aurora-B kinase inhibitor AZD1152 , 2007, Oncogene.

[48]  H. Koeffler,et al.  AZD1152, a novel and selective aurora B kinase inhibitor, induces growth arrest, apoptosis, and sensitization for tubulin depolymerizing agent or topoisomerase II inhibitor in human acute leukemia cells in vitro and in vivo. , 2007, Blood.

[49]  R. König,et al.  A probability-based approach for the analysis of large-scale RNAi screens , 2007, Nature Methods.

[50]  Rajesh Odedra,et al.  AZD1152, a Selective Inhibitor of Aurora B Kinase, Inhibits Human Tumor Xenograft Growth by Inducing Apoptosis , 2007, Clinical Cancer Research.

[51]  U. Kees,et al.  The Role of MYCN in the Failure of MYCN Amplified Neuroblastoma Cell Lines to G1 Arrest After DNA Damage , 2006, Cell cycle.

[52]  Kevin C Oeffinger,et al.  Chronic health conditions in adult survivors of childhood cancer. , 2006, The New England journal of medicine.

[53]  D. Rowitch,et al.  Inhibition of phosphatidylinositol 3-kinase destabilizes Mycn protein and blocks malignant progression in neuroblastoma. , 2006, Cancer research.

[54]  M. Loda,et al.  The Aurora kinase inhibitor VX-680 induces endoreduplication and apoptosis preferentially in cells with compromised p53-dependent postmitotic checkpoint function. , 2006, Cancer research.

[55]  A. Pession,et al.  The p53 regulatory gene MDM2 is a direct transcriptional target of MYCN in neuroblastoma. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[56]  J. Lunec,et al.  The p53 pathway and its inactivation in neuroblastoma. , 2003, Cancer letters.

[57]  P. McKenzie,et al.  Wild-type p53 can induce p21 and apoptosis in neuroblastoma cells but the DNA damage-induced G1 checkpoint function is attenuated. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[58]  D. Stram,et al.  Identification of subsets of neuroblastomas by combined histopathologic and N-myc analysis. , 1995, Journal of the National Cancer Institute.

[59]  M. Schwab,et al.  Non-syntenic amplification of MDM2 and MYCN in human neuroblastoma. , 1995, Oncogene.

[60]  L. Lum,et al.  Wnt Signaling , 2016, Methods in Molecular Biology.

[61]  S. Robinson,et al.  Small Molecule Inhibitors of Aurora-A Induce Proteasomal Degradation of N-Myc in Childhood Neuroblastoma. , 2016, Cancer cell.

[62]  G. Shapiro,et al.  Aurora kinase inhibition as an anticancer strategy. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.